Replimune Group, Inc. announced the appointment of Christy Oliger to the company's Board of Directors effective December 1, 2021. Previously Ms. Oliger was Senior Vice President of the Oncology Business Unit at Genentech responsible for all commercial activities in the US. Ms. Oliger spent two decades with Genentech, holding a number of leadership roles including Senior Vice President, IMPACT Business Unit; Vice President, Pharma Portfolio Management; Vice President, Portfolio Planning and Vice President, Hematology Marketing and Sales. Prior to Genentech, Ms. Oliger held management positions at Schering-Plough. Ms. Oliger currently serves as a member of the board of Karyopharm Therapeutics Inc., Reata Pharmaceuticals, Inc. and Sierra Oncology, Inc. The Board also appointed Ms. Oliger as a member of the Board?s Audit Committee and Research and Development Committee, in each case, effective as of the Effective Date.